TherapeuticsMD Inc (TXMD)

[TechKim]

It is not all bad is why their is still a reasonable share price value. TXMD could partner with a pharma. TXMD could still do a number of things.

Besides there has already been a 30 day endometrial study that was safe. I doubt there would be any significant change for a year long endometrial safety study. I ask myself did the competition in the same category ever have to provide a year long endometrial safety study? Almost seems like the FDA set the company up for failure. The company did what they were lead to believe needed to be done. Then the FDA changes course or is it that there was a different group of folks doing the final determinations verses those giving directions?


For now the bottom line is for a long range endometrial study to be done unless things change.

We do know one thing, as things stand. The product works. The safety is clean on a 30 day endometrial study. I would like to know where is the evidence that suggests a long range endometrial study needs to be done?